The prefilled syringes market is estimated to be worth over USD 2.5 billion by 2030
Roots Analysis has announced the addition of "Prefilled Syringes Market (5th Edition), 2020-2030" report to its list of offerings.
By: Roots Analysis
To order this 550+ page report, which features 150+ figures and 290+ tables, please visit this link
Key Market Insights
100 prefilled syringes are presently available / under development
Around 70% of these products have glass barrels. It is worth mentioning that majority (16) of the plastic barrel syringes are fabricated using cyclo olefin polymer.
Around 30 companies claim to manufacture add-on / integrated syringe safety products
Examples of players that manufacture add-on safety devices include (in alphabetic order, no selection criteria) Alfa Corpuscles, Biocorp, Credence Medsystems, Nemera, Schreiner Medipharm and Tip-Top.
In order to gain competitive edge in the market, manufacturers are actively engaged in developing patient friendly products
The report features a detailed competitiveness analysis of the various prefilled syringes, taking into consideration the supplier power (based on the employee size of developer / manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement / user-friendliness and other distinguishing features.
Close to 90 drugs have been approved in combination with prefilled syringes, over the last seven years
Interestingly, majority (53%) of the abovementioned combination products are antibody-based drug candidates. Currently, the next most popular class of therapeutics is vaccines, representing more than 15% of approved prefilled syringe combination products.
110+ clinical candidates are likely to be developed in combination with prefilled syringes in future
The report features insights on the likelihood of over 250+ marketed products and pipeline candidates, being developed in combination with prefilled syringes. Further, we identified 100+ innovator companies that are likely to enter into partnership with prefilled syringe manufacturers in the foreseen future
Currently, the big pharma focus is on developing prefilled combination products for autoimmune disorders
Insights on the initiatives of the top 20 pharmaceutical companies, highlighting their present priorities in terms of therapeutic areas and type of drug product to be developed in combination with prefilled syringes, are available in the full report.
For additional details, please visit
or email firstname.lastname@example.org (mailto:sales@
+1 (415) 800 3415
+44 (122) 391 1091